Showing 6281-6290 of 7112 results for "".
- PreCision Dermatology Appoints Chief Operating Officerhttps://practicaldermatology.com/news/20130307-precision_dermatology_appoints_chief_operating_officer/2459601/Robert Moccia has been appointed to the newly created position of Chief Operating Officer of PreCision Dermatology, Inc. In that role, all operating functions of PreCision will report to Mr. Moccia. In addition, Mr Moccia will serve as the President of Onset Dermatologics, LLC, a wholly owned subsid
- Novan Therapeutics Presents Data for Potential Topical Agent that Reduces Sebum in Acne Patientshttps://practicaldermatology.com/news/20130228-novan_therapeutics_presents_data_for_potential_topical_agent_that_reduces_sebum_in_acne_patients/2459602/Recent in vitro and animal testing data from Novan Therapeutics indicate that the company's drug candidate, SB204, could lead to a topical treatment for acne that reduces oil production in the skin. Dr. Diane Thiboutot, Professor of Dermatology at Penn State Hershey College of Medicine, notes that,
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatiti
- CeraVe Launches Seven New Sunscreens with Barrier-Repairing Ceramideshttps://practicaldermatology.com/news/20130225-cerave_launches_seven_new_sunscreens_with_barrier-repairing_ceramides/2459609/Seven newCeraVe sunscreening products are now available in the Sun Protection aisle at drugstores and mass market retailers nationwide. The CeraVe Sun Care line, developed with dermatologists, includes products for the face and body with various applications offe
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Sate
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-